New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics
Introduction The rise of antimicrobial resistance, especially among Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor (BL/BLI) combinations. Recently approved agents—cefepime/enmetazobactam, aztreonam/avibactam, and sulbactam/durlobactam—target resistant pathogens like…